Yotam Ottolenghi described opening his new restaurant in Edinburgh a “leap of faith” in a climate of rising costs, taxes and national insurance, with restaurants being less profitable than they once were.

A new slate of #optogenetic# tools enables scientists to finely control G protein signaling in excitable cells—providing a flexible method that might also be used therapeutically for disorders that disrupt the excitability of cells. @SciSignal

A new slate of #optogenetic# tools enables scientists to finely control G protein signaling in excitable cells—providing a flexible method that might also be used therapeutically for disorders that disrupt the excitability of cells. @ruhrunibochum

Anyone here investing in optogenetics companies? I studied optogenetics on my own a few years ago, and while I found the science fascinating, there were still some pretty significant limitations at the time — efficient opsin/gene delivery, limited light penetration into deep tissue, and the invasiveness of optical fibers or other implanted light-delivery hardware. It always felt like an incredibly interesting technology, but with a big gap between what works in the lab and what can actually scale clinically. I haven’t followed the space closely for a while, so I’m curious how much has changed since then. From an investment perspective, are there any companies or recent breakthroughs in optogenetics worth paying attention to?

"We were slightly cheated." Chef Yotam Ottolenghi tells Mishal Husain it was wrong to cut business rates on pubs but not restaurants — and explains what he wants to hear from UK Chancellor John Healey in this week's budget. Listen at or watch The Mishal Husain Show at